Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Access to Orphan Drugs in the EU
21 October 2010
Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr…
Biomedical and Health Research Spillovers in the UK
14 October 2010
Research spillovers exist when research by one organisation creates increased output for other organisations that operate in the same or other sector of the economy. Given…
New Antimicrobial Drugs: EU Policy Options
4 October 2010
Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development…
Value Based Pricing in the UK
7 September 2010
Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article…
Defining Benefit Through Willingness to Pay
24 August 2010
Since 2007, new medications may be paid for by the statutory health insurance funds (GKV) in Germany only if they are cost-effective. Willingness-to-pay analyses can be…
Biosimilars and Data Exclusivity
8 June 2010
Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of ‘traditional generics’ is a…
The Impact of Biosimilars on Markets
24 May 2010
The availability of biosimilars — ‘copies’ of biologics — is very recent and limited so far to only a few products. Projecting the impact on markets…
Evaluating Medical Innovation: The Societal View
8 April 2010
In a recent OHE Briefing, five leading European experts in health economics provide a comprehensive international review of changes in health economic evaluation and the reasons…
Biosimilars: How Much Entry and Price Competition Will Result?
1 December 2010
This publication reports on a seminar intended to encourage further thought about the distinguishing characteristics of the market for biosimilars and the implications of these for…